Neurocrine settles Lupin patent litigation; generic INGREZZA entry set for March 1, 2038

NEUROCRINE BIOSCIENCES INC

Settled with Lupin Limited and Lupin Pharmaceuticals; Lupin may sell generic INGREZZA starting March 1, 2038, or earlier under certain circumstances.
Prior settlements with Sandoz/Crystal and Teva also allow generic entry on March 1, 2038, subject to earlier launch conditions.
Remaining patent litigation against another ANDA filer is ongoing with trial scheduled for January 2, 2024.
Agreement will be submitted to FTC and DOJ as required by law.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.